Glioblastoma (GB) is the most severe form of brain cancer, with a 12-15 month median survival. Surgical resection, temozolomide (TMZ) treatment, and radiotherapy remain the primary therapeutic options for GB, and no new therapies have been introduced in recent years. This therapeutic standstill is primarily due to preclinical approaches that do not fully respect the complexity of GB cell biology and fail to test efficiently anti-cancer treatments. Therefore, better treatment screening approaches are needed. In this study, we have developed a novel functional precision medicine approach to test the response to anticancer treatments in organoids derived from the resected tumors of glioblastoma patients.

Metabolic-imaging of human glioblastoma live tumors: A new precision-medicine approach to predict tumor treatment response early

Cardarelli, Francesco;
2022-01-01

Abstract

Glioblastoma (GB) is the most severe form of brain cancer, with a 12-15 month median survival. Surgical resection, temozolomide (TMZ) treatment, and radiotherapy remain the primary therapeutic options for GB, and no new therapies have been introduced in recent years. This therapeutic standstill is primarily due to preclinical approaches that do not fully respect the complexity of GB cell biology and fail to test efficiently anti-cancer treatments. Therefore, better treatment screening approaches are needed. In this study, we have developed a novel functional precision medicine approach to test the response to anticancer treatments in organoids derived from the resected tumors of glioblastoma patients.
Settore FIS/07 - Fisica Applicata(Beni Culturali, Ambientali, Biol.e Medicin)
FLIM (fluorescence lifetime imaging microscopy); drug response assay; glioblastoma; metabolic imaging; predictive model
File in questo prodotto:
File Dimensione Formato  
fonc-12-969812.pdf

accesso aperto

Descrizione: Manuscript
Tipologia: Published version
Licenza: Creative commons
Dimensione 14.66 MB
Formato Adobe PDF
14.66 MB Adobe PDF Visualizza/Apri
fonc-12-969812-fonc-12-969812-parte1.pdf

accesso aperto

Descrizione: Parte prima (p. 1-9)
Tipologia: Published version
Licenza: Creative commons
Dimensione 9.45 MB
Formato Adobe PDF
9.45 MB Adobe PDF Visualizza/Apri
fonc-12-969812-fonc-12-969812-parte2.pdf

accesso aperto

Descrizione: Parte seconda (p. 10-18)
Tipologia: Published version
Licenza: Creative commons
Dimensione 4.88 MB
Formato Adobe PDF
4.88 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11384/125185
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact